Alnylam Pharma (ALNY)
303.64
0.00 (0.00%)
Upcoming Events
Latest Headlines
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
June 5, 2026 8:17 AM - StreetInsider
Alnylam partners with Inceptive in $2B AI collaboration for drug discovery
June 3, 2026 4:45 PM - StreetInsider
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
June 3, 2026 4:45 PM - BizWire
Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 01 Filed by: PYOTT DAVID E I
June 3, 2026 4:25 PM - SEC Filing
Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 01 Filed by: Cravatt Benjamin
June 3, 2026 4:24 PM - SEC Filing
Form 3 ALNYLAM PHARMACEUTICALS, For: Jun 01 Filed by: Cravatt Benjamin
June 3, 2026 4:21 PM - SEC Filing
Form 144 ALNYLAM PHARMACEUTICALS, Filed by: PYOTT DAVID E I
June 1, 2026 4:25 PM - SEC Filing
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
May 28, 2026 4:07 PM - StreetInsider
Form 8-K ALNYLAM PHARMACEUTICALS, For: May 20
May 27, 2026 4:31 PM - SEC Filing
Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Sigal Charles Elliott
May 22, 2026 4:21 PM - SEC Filing
Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: SCHULMAN AMY W
May 22, 2026 4:19 PM - SEC Filing
Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Reitan Colleen F
May 22, 2026 4:17 PM - SEC Filing
Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: PYOTT DAVID E I
May 22, 2026 4:15 PM - SEC Filing
Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: KELLOGG PETER N
May 22, 2026 4:13 PM - SEC Filing
Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: HAMBURG MARGARET A
May 22, 2026 4:11 PM - SEC Filing
Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: BRANDICOURT OLIVIER
May 22, 2026 4:09 PM - SEC Filing
Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Ausiello Dennis A
May 22, 2026 4:07 PM - SEC Filing
Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Arbuckle Stuart A
May 22, 2026 4:05 PM - SEC Filing
JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms
May 20, 2026 3:10 PM - StreetInsider
JPMorgan Reinstates Alnylam Pharmaceuticals (ALNY) at Overweight
May 20, 2026 4:30 AM - StreetInsider
Alnylam Issues 2025 Corporate Responsibility Report
May 19, 2026 8:30 AM - BizWire
Citi Starts Alnylam Pharmaceuticals (ALNY) at Buy
May 18, 2026 4:14 PM - StreetInsider
Form 4 ALNYLAM PHARMACEUTICALS, For: May 13 Filed by: SCHULMAN AMY W
May 14, 2026 4:18 PM - SEC Filing
Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Capital World Investors
May 14, 2026 1:56 PM - SEC Filing
Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Capital Research Global Investors
May 14, 2026 10:20 AM - SEC Filing
Alnylam presents vutrisiran data showing benefits across ATTR-CM patients
May 12, 2026 5:27 AM - StreetInsider
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patien
May 12, 2026 2:30 AM - BizWire
Alnylam to Webcast Presentations at Upcoming Investor Conferences
May 7, 2026 8:00 AM - BizWire
Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: FMR LLC
May 6, 2026 11:01 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
May 5, 2026 7:29 AM - StreetInsider
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
May 4, 2026 8:30 AM - BizWire
Alnylam Pharmaceuticals (ALNY) PT Lowered to $447 at Bernstein SocGen Group
May 1, 2026 9:52 AM - StreetInsider
Alnylam Pharmaceuticals (ALNY) PT Raised to $370 at Morgan Stanley
May 1, 2026 9:13 AM - StreetInsider
Alnylam Pharmaceuticals (ALNY) PT Raised to $377 at Wells Fargo
May 1, 2026 7:53 AM - StreetInsider
Alnylam Pharmaceuticals (ALNY) PT Lowered to $445 at RBC Capital
May 1, 2026 6:36 AM - StreetInsider
Form 10-Q ALNYLAM PHARMACEUTICALS, For: Mar 31
April 30, 2026 8:21 AM - SEC Filing
Form 8-K ALNYLAM PHARMACEUTICALS, For: Apr 30
April 30, 2026 8:08 AM - SEC Filing
Alnylam Pharma (ALNY) Tops Q1 EPS by 108c, provides guidance
April 30, 2026 8:02 AM - StreetInsider
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
April 30, 2026 8:00 AM - BizWire
Form SCHEDULE 13G ALNYLAM PHARMACEUTICALS, Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 4:45 PM - SEC Filing
U.S. Biotech stocks: Q1 earnings previews
April 26, 2026 8:00 PM - StreetInsider
Alnylam Pharmaceuticals (ALNY) PT Lowered to $448 at Bernstein SocGen
April 24, 2026 8:34 AM - StreetInsider
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026 8:30 AM - Globe NewsWire
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
April 16, 2026 8:00 AM - BizWire
Alnylam Pharmaceuticals (ALNY) PT Lowered to $505 at Truist Securities
April 13, 2026 7:09 AM - StreetInsider
Form 4 ALNYLAM PHARMACEUTICALS, For: Apr 02 Filed by: McLaughlin Melissa
April 7, 2026 4:21 PM - SEC Filing
Form 3 ALNYLAM PHARMACEUTICALS, For: Mar 25 Filed by: McLaughlin Melissa
April 7, 2026 4:17 PM - SEC Filing
Form ARS ALNYLAM PHARMACEUTICALS, For: Dec 31
April 6, 2026 5:02 PM - SEC Filing
Form DEFA14A ALNYLAM PHARMACEUTICALS,
April 6, 2026 4:32 PM - SEC Filing
Form DEF 14A ALNYLAM PHARMACEUTICALS, For: May 20
April 6, 2026 4:31 PM - SEC Filing
Form 144 ALNYLAM PHARMACEUTICALS, Filed by: McLaughlin Melissa
April 6, 2026 4:06 PM - SEC Filing
Alnylam presents cardiovascular drug data at medical conference
March 30, 2026 1:00 PM - StreetInsider
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
March 30, 2026 1:00 PM - BizWire
Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: VANGUARD GROUP INC
March 26, 2026 3:25 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
March 26, 2026 6:40 AM - StreetInsider
Stifel on Alnylam Pharmaceuticals (ALNY): 'positively biased after the pullback'
March 25, 2026 11:39 AM - StreetInsider
BofA on Alnylam (ALNY): 'AI-enabled diagnostics will help increase diagnosis rates'
March 24, 2026 3:10 PM - StreetInsider
Morgan Stanley: 'we see Amvuttra as well positioned'
March 24, 2026 3:08 PM - StreetInsider
Alnylam partners with Viz.ai and American Heart Association on ATTR-CM care
March 24, 2026 7:30 AM - StreetInsider
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
March 24, 2026 7:30 AM - BizWire
Jefferies Downgrades Alnylam Pharmaceuticals (ALNY) to Hold
March 16, 2026 12:54 AM - StreetInsider
Alnylam to Webcast TTR Investor Webinar
March 10, 2026 8:00 AM - BizWire
Full Article List
